International Journal of Antimicrobial Agents

Background and Aims The optimal treatment for first episodes and first recurrences of Clostridioides difficile infections (CDI) is unknown and there is emerging evidence for pulse and taper (P-T) regimens. Therefore, we sought to estimate the relative efficacy of treatment options. Methods MEDLINE and CENTRAL were searched from database inception to May 21, 2025 and unpublished conference abstracts were searched from recent infectious disease conferences. RCTs on the treatment of first episodes or first recurrences of CDI comparing fixed-dose or P-T regimens of fidaxomicin or vancomycin were included. The primary and secondary outcomes were 40- and 56-day CDI recurrence, respectively. A random-effects network meta-analysis on the risk ratio (RR) scale was conducted using a standard regimen (10-14 days) of vancomycin as the comparator. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Results 8 RCTs were included comprising a total of 2181 patients. For 40-day recurrence, fidaxomicin P-T had the highest probability of ranking best (RR=0.10, 95%Confidence Interval [95%CI]=0.10-0.49, SUCRA=1.00), followed by vancomycin P-T (RR=0.49, 95%CI=0.32-0.76, SUCRA=0.61), fixed-dose fidaxomicin (RR=0.61, 95%CI=0.49-0.76, SUCRA=0.39), and, finally, fixed-dose of vancomycin (SUCRA=0.00). The treatments ranked in the same order for 56-day recurrence, though only 3 RCTs reported on this timepoint. Conclusion Vancomycin P-T, fidaxomicin P-T, and fixed-dose fidaxomicin were all superior to a fixed-dose vancomycin. Head-to-head comparative effectiveness RCTs are needed to quantify their relative effect sizes of and impact on long-term prevention of recurrent CDI.

Background: Antimicrobial resistance (AMR) disproportionately affects low- and middle-income countries (LMICs) such as Pakistan, where obstetric and gynaecological (OBGYN) patients carry high antibiotic exposure. Specialty-specific drug utilization data with concurrent stewardship audit remain scarce. This study evaluated antibiotic prescribing patterns, consumption metrics, and antimicrobial stewardship program (AMS) compliance in OBGYN inpatients at a public sector tertiary care hospital. Methods: A prospective cross-sectional study was conducted in OBGYN wards of Dow University Hospital, Karachi, from 1 September to 31 October 2025. Women receiving [≥]1 systemic antibiotic were included. Daily AMS rounds were conducted by an Infectious Diseases physician and pharmacist. Antibiotic consumption was measured as Defined Daily Doses (DDD) and Days of Therapy (DOT) per 1,000 patient-days (total = 821). Antibiotics were classified by WHO AWaRe (2023) framework. Results: Of 812 total admissions, 278 patients (34.2%) received [≥]1 antibiotic and were enrolled (205 obstetric, 73 gynaecological), generating 636 prescriptions (mean 2.29/patient). Surgical prophylaxis was the predominant documented indication (213, 33.5%); 65.1% carried no documented indication. By AWaRe classification, 53.6% were Access-group and 46.1% Watch-group. Ceftriaxone (38.4%) and metronidazole (36.8%) together represented 75.2% of prescriptions. Combined DDD/1,000 patient-days was 1,758.6 and DOT/1,000 patient-days was 1,852.7. AMS compliance was 0%. Conclusions: This study documents high antibiotic prescribing burden, near-universal documentation failure, and zero AMS compliance in OBGYN inpatients at a Pakistani public sector hospital. The predominance of Watch-group antibiotics and undocumented surgical prophylaxis highlights structural stewardship gaps. Findings support urgent need for institutional OBGYN antibiotic guidelines and structured pharmacist-led AMS programs.

Controlled human infection models (CHIMs) are increasingly used in infectious disease research to study pathogen dynamics and evaluate interventions under controlled conditions. However, these studies are resource-intensive and involve ethical and safety constraints, making efficient study design critical. Dose-finding is a key early component in CHIMs, where the aim is to identify a challenge dose that achieves a target infection probability. Traditional rule-based designs are commonly used but can be inefficient, motivating the use of model-based adaptive approaches such as the Bayesian Continual Reassessment Method (CRM). Although CRM has been extensively studied and widely adopted in Phase I oncology trials for identifying the maximum tolerated dose of therapeutics, its application in CHIM settings remains limited, particularly when the endpoint of interest is infection. This tutorial provides step-by-step guidance for implementing a Bayesian CRM in dose-finding CHIMs, using an oropharyngeal Neisseria gonorrhoeae challenge as a motivating case study. The framework outlines key design components, including dose-grid specification, dose-response model, prior elicitation, Bayesian updating, decision rules, and stopping criteria, with particular emphasis on a clinically interpretable parameterisation. Trial operating characteristics are evaluated through simulation studies under multiple dose-response scenarios and prior-predictive analyses, and compared with a commonly used '3+3' type rule-based design. This work highlights the advantages of Bayesian model-based designs for dose-finding in CHIMs over classic rule-based designs and provides a structured, reproducible framework for implementing CRM, supporting their application in future CHIM studies.

Background and objectives Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of cirrhosis with ascites, carrying one- and two-year mortality rates exceeding 70% and 80%, respectively. Fluoroquinolone prophylaxis is the cornerstone of SBP prevention. Real-world longitudinal data on prescribing practices and clinical outcomes from Indian tertiary care centers are sparse. We aimed to evaluate fluoroquinolone prescribing patterns, guideline adherence, and six-month clinical outcomes in SBP patients at a tertiary academic center in North India. Methods This was a pre-specified sub-analysis of a 15-month analytical longitudinal study at AIIMS Rishikesh. Adults (age >/=18 years) admitted with SBP and initiated on fluoroquinolone prophylaxis were enrolled consecutively and followed for six months. Prescribing practices were compared against EASL and AASLD recommendations. The primary outcome was the rate of guideline-directed prescribing. Secondary outcomes included clinical cure at discharge, six-month cure, relapse, regimen modification, adverse drug reactions, and treatment compliance. Categorical variables were compared by Fisher's exact test or chi-squared test (SPSS). Results Forty-eight SBP patients were included (mean age 44.75 +/- 11.94 years; 85.4% male). Guideline-directed fluoroquinolone prophylaxis was prescribed to all patients (100%). Norfloxacin 400 mg once daily was predominant (85.4%), followed by levofloxacin (10.4%) and moxifloxacin (4.2%). Cure at discharge was 85.4%. At six months, 64.6% maintained sustained cure and 22.9% relapsed. Regimen modification occurred in 22.9%, most commonly antimicrobial substitution. Nausea was the only adverse drug reaction (4.8%). Treatment compliance was 73.8%. No patient underwent therapeutic drug monitoring. Conclusions Fluoroquinolone prescribing for SBP prophylaxis at AIIMS Rishikesh was fully concordant with standard guidelines. Despite complete adherence, a relapse rate of 22.9% and frequent regimen modification underscore the limitations of long-term fluoroquinolone prophylaxis, likely reflecting emerging quinolone resistance. Strengthening antimicrobial stewardship is essential to sustain prophylaxis effectiveness in Indian tertiary care settings.

Each year, over 50 million children receive preventive malaria treatment. However, to date there has been no consensus on the most effective antimalarial drugs to use, especially given geographic differences in drug resistance. Here, we conduct a systematic review comparing the effectiveness of the most commonly used antimalarial chemopreventive regimen, sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ), with other antimalarial drugs in preventing new infections. We searched MEDLINE, Embase, Global Health, PubMed and WWARN clinical trial databases until 06 December 2025 for studies satisfying the inclusion criteria. Studies were included if they were peer-reviewed, randomised-controlled studies in Africa, measuring incidence of infection or clinical episodes of Plasmodium falciparum malaria for at least 28 days post-treatment. We also compiled data on the prevalence of markers of resistance in the parasite dhfr, dhps and mdr1 genes in the study areas. We conducted meta-analyses of incidence rates, with subgroup analyses by drug resistance levels. This review is registered on PROSPERO (CRD42024577149). We identified 27 studies representing 38,252 participants in 32 sites across 13 countries. In pooled analysis, SP+AQ reduced incidence of malaria by 54.6% (95% CI: 33.8-68.8%) compared to SP alone, including significantly outperforming SP even in areas with low SP resistance. These findings suggest that countries currently using SP alone for chemoprevention should consider switching to SP+AQ. Where AQ resistance remains low, available evidence suggests SP+AQ remains efficacious for malaria chemoprevention. SP+AQ was comparable to the artemisinin-based treatment, dihydroartemisinin-piperaquine across all studies (incidence rate ratio 0.93; 95% CI 0.78-1.11). By resistance levels, SP+AQ had slightly higher efficacy in areas with low SP and AQ resistance but had comparable or slightly lower efficacy in areas with higher resistance. Using artemisinin-based treatments for chemoprevention must be balanced against the risk of worsening artemisinin resistance in Eastern and Southern Africa. This study was funded by the UK Royal Society.

Background: Urinary tract infection (UTI) is the most common secondary condition among people with spinal cord injury/disease (SCI/D). Intravesical Lacticaseibacillus rhamnosus GG (LGG) is an antibiotic-sparing approach to managing urinary symptoms. Objective: Determine the optimal number of doses of intravesical LGG for urinary symptom reduction. Design: Prospective, randomized, two-arm dosing trial. Setting: National recruitment with a local subsample providing urine samples in Washington, DC, USA. Participants: Adults with SCI/D and neurogenic lower urinary tract dysfunction (NLUTD) who use intermittent catheterization (IC); 177 enrolled and randomized (intention-to-treat), with 76 compliant instillers (39 low-dose, 37 high-dose) in the per-protocol analytic sample. Interventions: Two (2 doses/24 hours) or four (4 doses/36 hours) intravesical LGG regimens, self-initiated in response to cloudier or malodorous urine per the Self-Management Protocol using Probiotics (SMP-Pro). Main Outcome Measures: Primary: proportion achieving [≥]20% reduction on the Urinary Symptom Questionnaire for Neurogenic Bladder-Intermittent Catheter version (USQNB-IC). Secondary: urinary biomarkers (leukocyte esterase, nitrite, white blood cells, urinary neutrophil gelatinase-associated lipocalin [uNGAL]) and standard urine culture (SUC) in a local subsample. Results: By Day 2, 57.9% (63.8% low-dose; 51.2% high-dose) achieved [≥]20% total symptom reduction; high-dose success rose to 70.0% by Day 4. Thirty percent of high-dose participants did not respond at either time point and could not be distinguished from responders by demographics or urine biomarkers. Urinary biomarkers and SUC were unchanged pre- to post-instillation. No serious adverse events were adjudicated as attributable to intravesical LGG by an independent Data Safety Monitoring Board (DSMB). Conclusions: A two-dose course of intravesical LGG yields clinically meaningful symptom improvement in the majority of people with SCI/D and NLUTD who use IC; four doses benefits a meaningful subgroup of two-day non-responders, while a small cohort remains nonresponsive. These results provide preliminary dosing guidance and support progression to a definitive trial.

Antimicrobial resistance (AMR) is an ever-increasing threat to population health. Industrial, environmental and societal factors are increasingly recognized as important contributors to AMR within communities. Here, we investigated the spatial distribution of AMR genes (ARGs) across Alberta, Canada and their association with socio-economic, immigration-related, and agro-industrial characteristics using municipal wastewater-based surveillance. We analyzed monthly wastewater metagenomes collected between March 2022 and March 2023 across eleven municipalities, representing 39% of Alberta's population. Integration with census data enabled multivariate analysis, revealing that municipal resistome profiles were strongly structured along income and immigration-related population gradients. ARGs spanning 14 resistance classes exhibited distinct distributional patterns across income and immigration gradients, including contrasting associations among beta-lactam, aminoglycoside, and macrolide-lincosamide-streptogramin ARGs, consistent with heterogeneous selection pressures across sub-populations. These findings demonstrate the capacity of longitudinal wastewater surveillance to identify persistent population-level resistome patterns and highlight the importance of incorporating sociodemographic context into AMR surveillance and mitigation strategies.

Histidine-rich protein 2 (HRP2)-based rapid diagnostic tests (RDTs) are central to malaria case management in Africa but fail when Plasmodium falciparum parasites lack the pfhrp2 or pfhrp3 genes. Widespread deletions have been reported in Eritrea, Ethiopia, and Djibouti, yet no systematic data have been available from Somalia. Between May and October 2023, we collected 7148 dried blood spot (DBS) samples from patients with suspected malaria attending eight health facilities across seven regions in Somalia. Field HRP2/pan-lactate dehydrogenase (LDH) RDTs and microscopy were performed, and DNA was extracted from 301 RDT-positive and 173 RDT-negative DBS samples. A multiplex quantitative PCR assay targeting pfldh, pfhrp2, and pfhrp3 was used to identify deletions in pfldh-positive samples lacking pfhrp2 or pfhrp3 amplification, with mixed infections inferred from delta cycle threshold ({Delta}Ct) differences. Of 474 analysed samples, 301 (4.2%, 95% CI 3.7-4.7) were RDT or microscopy positive, and 159 (33.5%) were confirmed pfldh-positive by qPCR. Among these, six (3.8%, 95% CI 1.4-8.1) carried pfhrp2 deletions and 59 (37.1%, 95% CI 29.6-45.1) carried pfhrp3 deletions. Eleven infections (6.9%, 95% CI 3.5-12.1) produced discordant RDT outcomes, HRP-/LDH+ or RDT-negative despite pfldh positivity. Deletions were most frequent in Dolow, Luq, and Bosaso. A single isolate carried the pfk13 R622I mutation, confirming the first report of the emergence of an artemisinin partial resistance-associated in Dolow, Gedo region, Somalia. Pfhrp2/3 deletions causing false RDT results remain low in Somalia and the confidence interval overlaps with the 5% policy threshold for changing RDTs, indicating uncertainty that warrants larger-scale assessment. Pfhrp3 deletions are widespread and compromise the diagnostic redundancy of HRP2-based tests. Most deletion-carrying parasites remain detectable through the pan-LDH line, minimising immediate clinical risk but leading to systematic misclassification of P. falciparum as non-falciparum malaria. These findings support the continued use of HRP2/Pan-LDH RDTs but highlight high risk areas and emphasise the need for periodic and expanded molecular surveillance for prevalence trends to guide timely future diagnostic policy.

Objectives: To compare the effectiveness of povidone-iodine ear wash compared to no ear wash and oral cotrimoxazole compared to placebo given in addition to standard topical antibiotic treatment (ciprofloxacin drops) for chronic suppurative otitis media (CSOM) in Australian Aboriginal children. Methods: A randomised, parallel, 2 x 2 factorial design, assessor-blinded clinical trial in the remote Northern Territory of Australia. Aboriginal children with confirmed CSOM were eligible to be randomised into four treatment groups, allowing two primary treatment comparisons in a 2-in-1 trial approach. Participants received standard treatment (twice daily cleaning and topical ciprofloxacin drops) plus: i) either 16 weeks of pre-treatment povidone-iodine ear wash or no povidone-iodine ear wash; and ii) either 16 weeks of oral cotrimoxazole or placebo. Central randomisation with allocation concealment and triple-blinding of the oral antibiotic treatment arms was used. The relative risk (RR) and risk difference (RD) were estimated after adjustment for age, community, and the other intervention. The primary outcome was the proportion of children with any otorrhoea (clinical failure) after 16 weeks of treatment. Secondary outcomes included size of tympanic membrane (TM) perforation and amount of discharge, time to cessation of discharge, proportion of children with respiratory and other pathogens in ear discharge (at baseline and 16 weeks) and hearing levels (at 12 months). Findings: 280 children with CSOM were randomised and 270 had their primary outcome assessed. Clinical failure (presence of any ear discharge) after 16 weeks of treatment was 66/134 (49%) in the povidone-iodine group versus 69/136 (51%) in the no povidone-iodine group (RD= -1% (-12,11), p= 0.93) and 56/134 (42%) in the cotrimoxazole group versus 79/136 (58%) in the placebo group (RD=-16% (-28,-4), p=0.007). The amount of discharge, TM perforation size, the level of hearing impairment, and serious adverse events were not significantly different in both treatment comparisons. Anaerobic growth (24%), Pseudomonas aeruginosa (21%) and Haemophilus influenzae (17%) were the most common pathogens found in the ear discharge before treatment. Fungi or yeast (24%), Staphylococcus aureus (15%), and anaerobic growth (10%) were the common pathogens after 16 weeks of treatment, with no significant differences between groups. At 12 months post-randomisation, 55-60% of children had at least one discharging ear and there was no difference between treatment groups. Interpretation: Povidone-iodine ear washes did not contribute to better ear outcomes in this study. Cotrimoxazole for 16 weeks resulted in more children with clinical improvement to dry ears. Oral cotrimoxazole may play a role in reducing the burden of CSOM in populations with high rates of persistent disease.

Background: Diabetes mellitus is an increasing public health challenge in Sierra Leone, where access to diagnosis, treatment, and long-term care remains limited. Traditional medicine continues to play a significant role in disease management; however, ethnobotanical knowledge related to diabetes remains insufficiently documented. Methods: A cross-sectional ethnobotanical survey was conducted among 40 informants, including traditional healers, herbalists, and knowledgeable community members in Waterloo, Pendembu, and Bo. Data were collected using structured questionnaires administered via Kobo Toolbox and paper-based tools. Information on medicinal plants, plant parts used, preparation methods, routes of administration, and knowledge transmission pathways was obtained. Quantitative ethnobotanical indices, including Frequency of Citation (FC), Relative Frequency of Citation (RFC), and Informant Consensus Factor (ICF), were calculated. Results: A total of 21 medicinal plant species were documented. The most frequently cited species were Moringa oleifera (FC = 9; RFC = 0.225), Vernonia amygdalina (FC = 7; RFC = 0.175), and both Cassia siberiana and Telfairia occidentalis (FC = 6; RFC = 0.150). Leaves were the most commonly utilized plant part (40.9%), and decoction was the predominant preparation method (76.2%), with oral administration accounting for 95.2% of use. The Informant Consensus Factor (ICF = 0.69) indicated a relatively high level of agreement among informants. Knowledge was primarily transmitted through apprenticeship and inherited family practices. Conclusion: Traditional medicinal plants remain an important component of diabetes management in Sierra Leone. The high level of consensus among informants and the repeated citation of specific plant species suggest structured and culturally validated therapeutic practices. The findings provide a foundation for future phytochemical and pharmacological investigations and highlight the need for documentation, preservation, and sustainable utilization of ethnobotanical knowledge.

Importance Pharmacogenomic (PGx) guidelines can improve medication efficacy and reduce toxicity, but their application in pediatric intensive care units (PICUs) remains largely unexplored. Objective To determine the frequency of medications with established PGx guidelines administered in the PICU and assess the capacity of exome sequencing to capture PGx phenotypes for these medications. Design Retrospective cohort study integrating electronic medical record and exome sequencing data. Setting Morgan Stanley Children's Hospital of NewYork-Presbyterian, a single center tertiary care children's hospital. Participants A total of 4,939 children admitted to the PICU (2020 - 2024), and 192 children admitted to the PICU who underwent exome sequencing for research purposes (2015 - 2023). Exposure Critical illness requiring PICU admission. Main Outcomes and Measures Frequencies of administration of medications with established PGx guidelines in the PICU and the proportion of individuals with exome sequencing with identifiable PGx phenotypes. Results Among 4,939 PICU patients, 37.2% (n=1,837) received at least one medication with established PGx guidelines and 14.4% (n=712) received two or more such medications. Twenty PGx genes were implicated; CYP2C9 was most common (17.3%, n=853). An estimated 8.2% of patients received medications for which PGx-guided recommendations would have altered clinical management. Among 192 patients who underwent exome sequencing, at least one metabolizer phenotype was identified in 62% (n=119). Conclusions and Relevance Many critically ill children receive medications with established PGx guidelines. This study highlights an opportunity for more personalized medicine for critically ill children admitted to a tertiary care hospital and assesses the strengths and weaknesses of exome sequencing to uncover pertinent PGx phenotypes.

BACKGROUND: Half of positive blood cultures in pediatric emergency departments (PEDs) represent contaminants, driving unnecessary hospitalization, antibiotic exposure, and repeat visits. A clinical decision rule derived at CHU Sainte-Justine showed 99% sensitivity and 60% specificity for distinguishing bacteremia from contaminants but had not been externally validated. We sought to validate this rule in an independent pediatric cohort. METHODS: This retrospective diagnostic study spanned from January 2015 to May 2025 at a tertiary PED in Switzerland, using positive blood cultures from patients younger than 16 years. The four predictors (Gram-negative organisms or Gram-positive cocci in pairs or chains; time to positivity <17 hours; indwelling device; suspected osteoarticular infection) classified each case as low, moderate, or high risk. The primary outcome was bacteremia, adjudicated by two independent reviewers, based on organism identity and infectious disease specialist's assessment. Diagnostic accuracy was assessed with 95% CIs. RESULTS: Of 130 children enrolled (median age 3.8 years [IQR 0.9-9.9]; 61.5% male), 78 (60.0%) had true bacteremia. The rule yielded a sensitivity of 97.4% (95% CI, 91.0-99.7), specificity of 69.2% (95% CI, 54.9-81.3), positive predictive value of 82.6% (95% CI, 73.3-89.7), and negative predictive value of 94.7% (95% CI, 82.3-99.4). Both false-negatives were immunocompetent children with methicillin-susceptible Staphylococcus aureus bacteremia without indwelling devices. Among contaminants, 71% received antibiotics under usual care versus 31% classified as moderate or high risk by the rule. CONCLUSIONS: This first external validation supports the Sainte-Justine rule in a distinct pediatric population, preserving sensitivity with higher specificity. Multicenter validation is warranted before adoption.

Background: Leptospirosis causes around 1 million cases and 60,000 deaths globally annually, predominantly affecting flood-prone tropical regions. Transmitted through contact with water or soil contaminated by animal urine infected with Leptospira spp., this bacterial zoonosis is classified as a high-risk Group B infectious disease in Vietnam. However, epidemiological and clinical data are scarce, particularly in pediatric populations. This study evaluated clinical and laboratory characteristics of leptospirosis cases at the National Children's Hospital, Hanoi, from January 2023 to August 2025. Methodology : All children admitted with probable or confirmed leptospirosis were enrolled. Clinical and laboratory data were analyzed to characterize disease manifestations and identify risk factors for severe leptospirosis. This was defined by the presence of organ dysfunction, including liver or renal failure, hemorrhage (particularly pulmonary), aseptic meningitis, cardiac arrhythmias, pulmonary insufficiency, or hemodynamic collapse. Principal Findings : Of 84 patients (37 confirmed, 47 probable), the mean age was 9.4 years, with 52.4% male and over half aged [&ge;] 10 years. Fever was the most common presenting symptom (85.7%); gastrointestinal and renal manifestations were frequent, including oliguria in 26.2% of cases. Key laboratory abnormalities included elevated D-dimer (81.8%), elevated C-reactive protein (75.6%), hypoalbuminemia (74.3%), increased liver enzymes (AST 63.3%, ALT 53.2%), and renal impairment ({approx} 46%). Severe disease developed in 48.8% of patients, most frequently as acute kidney injury. Hematuria was independently associated with increased severity (OR = 4.89). Conversely, fever, higher baseline albumin, and longer symptom duration prior to hospitalization were associated with a significantly reduced risk of severe disease. Conclusions : Pediatric leptospirosis in this cohort frequently presented with systemic inflammation and multi-organ involvement, particularly renal impairment. Nearly half the patients developed severe disease. Early recognition of renal signs, especially hematuria, and careful monitoring of albumin levels are critical to identifying children at risk for severe progression and optimizing clinical management.

Study objective. Some acetaminophen-overdose patients develop hepatotoxicity despite acetylcysteine treatment. Established tools struggle to prospectively identify this cohort. We developed a model using only routine admission biomarkers to identify acetylcysteine-treated patients at highest risk, and compared it with the current benchmark, the alanine aminotransferase x acetaminophen product (ALTxAPAP). Methods. Retrospective cohort of all acetaminophen overdose admissions (ICD-10 T39.1) to three UK hospitals (2008-2024) with alanine aminotransferase (ALT) >1000U/L at admission. We fitted elastic-net logistic models stratified by presentation ALT. The outcome was peak ALT >1,000U/L. Performance was assessed on a 25% held-out test set and benchmarked against ALTxAPAP. Results. Of 4,705 admissions, 119 (2.5%) developed hepatotoxicity. The model used seven routine blood tests, four per stratum: acetaminophen, sodium, potassium and lymphocyte count where presentation ALT was <50U/L; ALT, bilirubin, alkaline phosphatase and lymphocyte count where it was 51-1,000U/L. In the test set (n=1,175) it achieved an area under the curve of 0.93 (95% CI 0.89-0.97) versus 0.82 (0.72-0.91) for ALTxAPAP (paired difference 0.11; 95% CI 0.01-0.22; p=0.03), with higher specificity and a higher positive likelihood ratio at every matched sensitivity. Matched to current ALTxAPAP >1,500 practice (sensitivity 89.7%), specificity was 82.5% versus 62.6% and the positive likelihood ratio 5.1 versus 2.4, more than halving false-positive escalations (171 versus 365 per 1,000 patients). Conclusion. A stratified model using only routine admission biomarkers identifies acetylcysteine-treated patients at highest residual hepatotoxicity risk, outperforming the ALTxAPAP rule across decision thresholds, supporting selection for intensified therapy.

Background: Bacteraemia is associated with poor outcomes but the diagnostic gold standard, peripheral blood culture, takes up to 24 hours to become clinically actionable, hampering early management decisions in suspected infection. Single predictors and existing sepsis risk scores discriminate poorly, and few multivariable bacteraemia models have been adequately validated in UK populations. Methods: We developed a logistic regression model, using backwards AIC based selection of predefined candidate predictors routinely available within hours of hospital attendance, in a retrospective cohort of 33,874 hospital encounters at University College London Hospitals (UCLH) between 2019 and 2024. Continuous predictors were modelled using restricted cubic splines and missing data handled using multiple imputation. Model performance was assessed via internal external cross validation and prediction instability analysis, before temporal validation in held-out 2024 UCLH data and external validation in 53,669 hospital encounters from the Infections in Oxfordshire Research Database (IORD). Results: Bacteraemia occurred in 5.2% of UCLH and 8.9% of IORD encounters, respectively. Twenty predictors were retained, spanning demographics, comorbidities, vital signs and blood tests. Discrimination was stable across development time periods (pooled c-statistic 0.82, 95%CI 0.81 to 0.84) and was maintained in temporal (0.83, 0.79 to 0.87) and external validation (0.83, 0.82 to 0.83), with excellent calibration in external validation (calibration slope 1.08 (1.05 to 1.11); calibration-in-the-large 0.01 (-0.02 to 0.04)). The model outperformed single predictors, established risk scores, and a reconstructed comparator model, and showed superior net benefit in decision curve analysis. Performance was consistent across age, sex, ethnicity and socioeconomic subgroups but degraded when blood cultures were sampled more than six hours after attendance and varied by likely infection site. Conclusions: This model accurately predicts bacteraemia using routinely collected data available within hours of hospital attendance, with performance maintained in a large, independent external validation cohort. It offers a generalisable, clinically interpretable tool to support early decision-making in suspected infection, pending further work to establish optimal implementation thresholds.

Background Bloodstream infections are a major cause of mortality, yet the primary testing method, blood cultures, have low positivity (<10%) and turnaround times of 24 - 48 hours. Many are taken from patients at low risk of infection, while some bloodstream infections are diagnosed late or missed entirely. We aimed to develop and externally validate machine learning models to improve targeting of blood culture testing. Methods In this retrospective cohort study, we used routinely collected clinical and laboratory data available around culture collection from a large multi-site NHS trust (Oxford University Hospitals; Infections in Oxfordshire Research Database), between 1 January 2016 and 17 March 2025. All blood cultures taken from adults and children were included. XGBoost models were trained to predict pathogenic blood culture positivity using a temporal split (training before 1 January 2024; held-out test thereafter). External validation used emergency department data (between 1st May 2019 and 30th April 2024) from University College London Hospitals. An additional analysis examined blood culture reallocation towards the highest-risk untested admissions. Findings 294,064 cultures were included (positivity 5.6%). In the temporal hold-out test set (n=46,339), AUROC (Area Under the Receiver Operating Characteristic) was 0.853 (95% CI 0.846 - 0.860), rising to 0.876 in emergency department patients, and the model was well calibrated (slope 1.046). In external validation (n=37,326), AUROC was 0.847 (95% CI 0.839 - 0.856) with preserved calibration. In a simulated resource-neutral reallocation, replacing the 10,000 lowest-risk sent cultures with the highest-risk untested emergency admissions yielded 627 additional positive cultures (28.3% relative increase in yield). Performance was reduced when restricted to data available at the point of culture collection (AUROC 0.769, 95% CI 0.760 - 0.779). Interpretation An externally validated, well calibrated machine learning model built from broadly available, routinely collected data could improve blood culture yield without increasing testing volume, supporting resource-neutral diagnostic stewardship across NHS sites.

Objectives: In some resource-limited settings the case-fatality rate of severe leptospirosis can exceed 50%. Early recognition of severe disease can expedite transfer to referral centres for advanced supportive care. The entirely clinical, 3-point SPiRO score can be calculated rapidly at presentation to predict a patients subsequent clinical course. In its derivation study, a SPiRO score of 0 had a negative predictive value (NPV) for intensive care unit (ICU) admission of 98% (95% confidence interval (CI): 96-99). In this validation cohort we sought to confirm the clinical utility of the SPiRO score and to compare its prognostic utility with other leptospirosis-specific and general disease severity scores. Methods: We examined consecutive adults presenting to high-caseload hospitals in tropical Australia with laboratory-confirmed leptospirosis between June 2016 and April 2026. The ability of the SPiRO score to predict requirement for ICU admission before hospital discharge was compared with that of the leptospirosis-specific QuickLepto score and commonly used disease severity scores, namely the SOFA, qSOFA, qSOFA-lactate, NEWS-2, qNEWS, UVA and the SIRS scores. Results: ICU admission was required in 62/309 (20%) episodes of leptospirosis. The SPiRO score performed as well as - or better than - all the other scores in predicting ICU admission. The Area Under the Receiver Operating Characteristic curve for the SPiRO score was 0.83 (95% CI: 0.77-0.89); only the SOFA score had a higher value: 0.84 (0.79-0.90), although the difference was not statistically significant (p=0.08). The SPiRO score had the highest NPV for ICU admission of any of the scores: 95 (95% CI: 91-97)%. Conclusions: The SPiRO score can be calculated easily at the bedside at presentation to expedite the recognition of patients with leptospirosis who are most likely to deteriorate. In resource-limited settings this entirely clinical score can also help reduce unnecessary escalation of care, optimising the use of finite health resources.

Background: Monoclonal antibodies have emerged as a prophylactic strategy to prevent symptomatic SARS-CoV-2 infection in immunocompromised individuals. However, the evolutionary and clinical implications of breakthrough infections under this regime remain unclear. Methods: A male in their 80s with a haematological/oncological diagnosis received a 2000 mg intravenous infusion of sotrovimab in March 2023 and was diagnosed with COVID-19 by RT-qPCR from a nasopharyngeal swab in August 2023. Weekly samples (n=24) were collected through February 2024 (171 days). All samples underwent whole-genome sequencing, with select mutations subjected to functional assessment. Findings: Sequencing identified the GE.1 lineage at all timepoints. An intra-host recombination event in ORF1ab (positions 8942-12458) was detected prior to 23 weeks post-detection, followed by a 14-fold increase in viral load (7.42e+06 to 1.00e+08 RNA copies/mL) and a marked shift in the viral population. E340D, a sotrovimab resistance mutation, was detected at low abundance (46%) within the first week post-infection, fluctuated over time, and was nearly fixed by week 15 (107 days) post-detection. We assessed five spike mutations - V36M, S98F, and V213G in the N-terminal domain, Y505P in the receptor-binding domain, and P681Q near the S1/S2 cleavage site - and additionally evaluated the impact of E340D. V36M conferred the highest infectivity across all cell lines, with the most significant effect in low-TMPRSS2 cells. While all mutations showed enhanced infectivity with the addition of E340D, the effect was most pronounced in mutations with lower baseline infectivity. The addition of E340D significantly decreased relative neutralizing titres for V36M, S98F, and V213G, enabling escape from neutralizing antibodies in XBB-responsive individuals, illustrating an enhanced phenotypic advantage. Patient neutralizing activity was absent pre-sotrovimab, and sotrovimab-induced neutralization was further compromised by selection of E340D. Interpretation: Sotrovimab pre-exposure prophylaxis in an immunocompromised patient did not prevent SARS-CoV-2 infection, and selected for resistant mutation E340D, with unexpected fitness consequences across non-receptor binding domain spike regions.

Background The 2022-2023 global mpox outbreak highlighted the critical need for robust genomic surveillance capabilities to track mpox virus (MPXV) evolution and transmission dynamics. Methods Building upon our established SARS-CoV-2 sequencing infrastructure, we implemented a Molecular Loop probe-based long-read sequencing approach using Pacific Biosciences Sequel II technology for comprehensive MPXV genomic surveillance across the United States (US). From August 2024 to June 2025, we generated 326 high-quality whole genome sequences from residual mpox-positive clinical specimens collected by Labcorp across all 10 US Department of Health and Human Services regions. Results Our analysis identified two samples containing clade Ib MPXV in January and June 2025 and captured shifting trends in clade IIb diversity, with 13 distinct lineages observed. We also identified multiple instances of large (~1.6-17.6kb) deletions proximal to the inverted terminal repeats in clade IIb genomes. APOBEC3 mutation analysis indicated substantial evidence of human-to-human transmission among both clades. Further, we observed significantly higher APOBEC3-associated SNPs per kilobase (P<0.001) in clade IIb genomic variable regions relative to their central conserved region. Our assay exhibited strong reproducibility across biological replicates from individual patients and accuracy was confirmed via parallel sequencing of select specimens by US Centers for Disease Control and Prevention (CDC) using metagenomic sequencing. We also demonstrated via custom simulation that our assay discriminates all known MPXV clades and lineages, including those we have not observed in the US. Conclusions Our integrated nationwide surveillance system facilitates real-time genomic tracking of outbreak evolution, with demonstrated capacity across SARS-CoV-2 and MPXV, positioning this platform for rapid deployment during future pathogen emergence.

Background: Opioid use disorder (OUD) is heritable, yet most genome-wide association studies (GWAS) have focused on European populations, leaving the genetic architecture of OUD in non-European populations underexplored. Methods: We conducted GWAS of OUD across three ancestries using electronic health records and genomic data from 52,357 All of Us Research Program participants (8,912 cases; 43,445 matched opioid-exposed controls; 48.5% female). Participants were stratified into European (EUR), African (AFR), and Admixed American (AMR) ancestry groups for logistic regression GWAS, with independent replication in the Million Veteran Program. We then applied the deep-learning model AlphaGenome to predict the tissue-specific transcriptomic and splicing consequences of top risk variants across 13 reward-pathway brain regions. Results: We identified and replicated a novel DDX6 risk locus, alongside established OPRM1 and FURIN signals. AlphaGenome predicted the DDX6 regulatory allele downregulates the stress-resistance gene FOXR1 in the nucleus accumbens, while the protective OPRM1 variant (rs1799971) upregulates OPRM1 expression across reward networks. Other signals of interest included IL6R and SHISA9 (EUR); GHR (AFR); and ASTN2 (AMR). Conclusions: This study identifies DDX6 as a novel OUD risk locus, replicates associations with OPRM1 and FURIN, and highlights biologically plausible ancestry-specific signals in AFR and AMR populations. We also replicated top variants in an independent population. Finally, integrating GWAS with deep-learning annotations provides specific, localized biological hypotheses to guide future experimental validation and targeted therapeutics.